Low-Level Rifampin Resistance and

Antitubercular Agents / pharmacology Bacterial Proteins / genetics DNA-Directed RNA Polymerases / genetics Drug Resistance, Bacterial / genetics Humans Microbial Sensitivity Tests Mutation Mycobacterium tuberculosis / genetics New York Pharmaceutical Preparations Rifampin / pharmacology Tuberculosis, Multidrug-Resistant
MIC Mycobacterium tuberculosis RIF WGS low-level resistance next-generation sequencing rifampin rpoA rpoB rpoC

Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
19 03 2021
Historique:
received: 20 07 2020
accepted: 05 09 2020
pubmed: 2 10 2020
medline: 9 7 2021
entrez: 1 10 2020
Statut: epublish

Résumé

Rapid and reliable detection of rifampin (RIF) resistance is critical for the diagnosis and treatment of drug-resistant and multidrug-resistant (MDR) tuberculosis. Discordant RIF phenotype/genotype susceptibility results remain a challenge due to the presence of

Identifiants

DOI: 10.1128/JCM.01885-20 PMID: 32999007 PMC: PMC8579749
pubmed: 32999007
pii: JCM.01885-20
doi: 10.1128/JCM.01885-20
pmc: PMC8579749
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
Pharmaceutical Preparations 0
DNA-Directed RNA Polymerases EC 2.7.7.6
Rifampin VJT6J7R4TR

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : OSELS CDC HHS
ID : U60 OE000103
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American Society for Microbiology.

Références

Respirol Case Rep. 2018 Sep 14;6(8):e00366
pubmed: 30237887
J Clin Microbiol. 2017 Feb;55(2):457-469
pubmed: 27903602
Int J Tuberc Lung Dis. 2014 Mar;18(3):357-62
pubmed: 24670576
Tuberc Res Treat. 2010;2010:938178
pubmed: 22567261
J Clin Microbiol. 2013 Aug;51(8):2641-5
pubmed: 23761146
BMC Infect Dis. 2019 Jan 3;19(1):3
pubmed: 30606116
Antimicrob Agents Chemother. 1996 Apr;40(4):1053-6
pubmed: 8849230
Sci Rep. 2019 Mar 14;9(1):4474
pubmed: 30872748
J Clin Microbiol. 2014 Jun;52(6):1846-52
pubmed: 24648554
J Clin Microbiol. 2013 Oct;51(10):3277-85
pubmed: 23884993
Tuberc Respir Dis (Seoul). 2017 Jul;80(3):270-276
pubmed: 28747960
J Clin Microbiol. 2010 Nov;48(11):4003-9
pubmed: 20810777
J Clin Microbiol. 2015 Apr;53(4):1137-43
pubmed: 25631807
J Clin Microbiol. 2002 Mar;40(3):1091-4
pubmed: 11880449
Tuberc Respir Dis (Seoul). 2018 Jul;81(3):222-227
pubmed: 29527837
PLoS One. 2010 May 28;5(5):e10893
pubmed: 20531942
J Clin Microbiol. 2003 May;41(5):2209-12
pubmed: 12734282
Eur J Biochem. 1981 Jun 1;116(3):621-9
pubmed: 6266829
Open Forum Infect Dis. 2016 Aug 24;3(3):ofw150
pubmed: 27704008
Emerg Microbes Infect. 2018 Jun 6;7(1):98
pubmed: 29872078
J Clin Microbiol. 2011 Jul;49(7):2688-90
pubmed: 21562104
Nat Commun. 2015 May 11;6:7119
pubmed: 25960343
Nat Genet. 2011 Dec 18;44(1):106-10
pubmed: 22179134
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29378712
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1881-4
pubmed: 9620922
Int J Infect Dis. 2018 Nov;76:109-119
pubmed: 29936318
Int J Tuberc Lung Dis. 2014 Oct;18(10):1255-7
pubmed: 25216843
J Clin Microbiol. 2014 Jul;52(7):2615-24
pubmed: 24829250
J Clin Microbiol. 2015 May;53(5):1752-3
pubmed: 25740782
Tuber Lung Dis. 1998;79(1):3-29
pubmed: 10645439
J Clin Microbiol. 2010 Apr;48(4):1182-8
pubmed: 20107097
Salud Publica Mex. 2015 Mar-Apr;57(2):177-9
pubmed: 26235779
Diagn Microbiol Infect Dis. 2013 Jun;76(2):187-96
pubmed: 23561273
PLoS One. 2012;7(6):e38431
pubmed: 22679504
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2807-12
pubmed: 26902762
J Antimicrob Chemother. 2011 Apr;66(4):730-3
pubmed: 21393153
Clin Infect Dis. 2012 Nov;55(9):1179-87
pubmed: 22865872
Antimicrob Agents Chemother. 2012 Dec;56(12):6080-7
pubmed: 23006760
Microb Genom. 2018 Feb;4(2):
pubmed: 29310751
Lancet Infect Dis. 2007 May;7(5):328-37
pubmed: 17448936
PLoS One. 2015 Jun 03;10(6):e0129207
pubmed: 26039194
Lancet. 1993 Mar 13;341(8846):647-50
pubmed: 8095569
PLoS One. 2016 Apr 05;11(4):e0152933
pubmed: 27045684
J Mol Biol. 1988 Jul 5;202(1):45-58
pubmed: 3050121
Int J Tuberc Lung Dis. 2012 Feb;16(2):216-20
pubmed: 22137551
J Clin Microbiol. 2009 Nov;47(11):3501-6
pubmed: 19759221
J Clin Microbiol. 2013 Aug;51(8):2633-40
pubmed: 23761144
Antibiotics (Basel). 2014 Jul 02;3(3):317-40
pubmed: 27025748
Open Forum Infect Dis. 2019 Feb 12;6(4):ofz065
pubmed: 31024968
J R Soc Interface. 2018 Jun;15(143):
pubmed: 29950511
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29540456
PLoS Med. 2015 Jun 23;12(6):e1001843; discussion e1001843
pubmed: 26103620
Int J Tuberc Lung Dis. 1997 Apr;1(2):115-21
pubmed: 9441074
Int J Mycobacteriol. 2020 Apr-Jun;9(2):121-137
pubmed: 32474533
J Antimicrob Chemother. 2013 Nov;68(11):2493-7
pubmed: 23759506
J Clin Microbiol. 1994 Apr;32(4):1095-8
pubmed: 8027320
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):9-14
pubmed: 28823010
J Clin Microbiol. 2017 Jun;55(6):1871-1882
pubmed: 28381603
PLoS One. 2013 Nov 06;8(11):e77712
pubmed: 24223122
BMJ Open. 2019 Nov 6;9(11):e031663
pubmed: 31699736
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Curr Opin Microbiol. 2006 Oct;9(5):461-5
pubmed: 16890008
Int J Tuberc Lung Dis. 2017 Jul 1;21(7):766-773
pubmed: 28513421
J Antimicrob Chemother. 1995 Feb;35(2):345-8
pubmed: 7759399
J Antimicrob Chemother. 1998 Nov;42(5):621-8
pubmed: 9848446
J Antibiot (Tokyo). 2014 Sep;67(9):625-30
pubmed: 25118103
J Clin Microbiol. 2014 Jun;52(6):2157-62
pubmed: 24740074
J Antimicrob Chemother. 2016 Feb;71(2):324-32
pubmed: 26538504
Sci Rep. 2018 Nov 30;8(1):17488
pubmed: 30504835

Auteurs

Joseph Shea (J)

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

Tanya A Halse (TA)

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

Donna Kohlerschmidt (D)

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

Pascal Lapierre (P)

Wadsworth Center, New York State Department of Health, Albany, New York, USA.
ORCID: 0000-0003-1238-0955

Herns A Modestil (HA)

New York City Department of Health and Mental Hygiene, New York, New York, USA.

Cheryl H Kearns (CH)

New York State Department of Health, Albany, New York, USA.

Felicia F Dworkin (FF)

New York City Department of Health and Mental Hygiene, New York, New York, USA.

Jennifer L Rakeman (JL)

Public Health Laboratory, New York City Department of Health and Mental Hygiene, New York, New York, USA.
ORCID: 0000-0002-9464-7723

Vincent Escuyer (V)

Wadsworth Center, New York State Department of Health, Albany, New York, USA.

Kimberlee A Musser (KA)

Wadsworth Center, New York State Department of Health, Albany, New York, USA kimberlee.musser@health.ny.gov.
ORCID: 0000-0003-1922-5405

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Low-Level Rifampin Resistance and
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › Low-Level Rifampin Resistance and
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Nucleotidyltransferases › RNA nucleotidyltransferases › DNA-directed RNA polymerases › Low-Level Rifampin Resistance and
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Low-Level Rifampin Resistance and
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Low-Level Rifampin Resistance and
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Low-Level Rifampin Resistance and
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Low-Level Rifampin Resistance and
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Low-Level Rifampin Resistance and
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Région du Centre-Atlantique › État de New York › Low-Level Rifampin Resistance and
questionsmedicales.fr › Préparations pharmaceutiques › Low-Level Rifampin Resistance and
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Low-Level Rifampin Resistance and
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Low-Level Rifampin Resistance and